DekaBank Deutsche Girozentrale trimmed its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 4.0% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 190,719 shares of the medical research company's stock after selling 7,929 shares during the period. DekaBank Deutsche Girozentrale owned about 0.11% of IQVIA worth $33,479,000 at the end of the most recent reporting period.
Other institutional investors also recently bought and sold shares of the company. American National Bank & Trust purchased a new stake in IQVIA during the 1st quarter worth $26,000. Golden State Wealth Management LLC lifted its stake in shares of IQVIA by 295.5% during the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock worth $31,000 after purchasing an additional 130 shares in the last quarter. ST Germain D J Co. Inc. boosted its position in shares of IQVIA by 66.1% in the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock worth $34,000 after buying an additional 76 shares during the period. GKV Capital Management Co. Inc. acquired a new stake in shares of IQVIA in the fourth quarter valued at about $39,000. Finally, Lee Danner & Bass Inc. purchased a new stake in shares of IQVIA during the 4th quarter valued at about $44,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.
IQVIA Stock Performance
Shares of NYSE:IQV traded down $2.80 during trading on Friday, hitting $162.73. 1,156,699 shares of the company traded hands, compared to its average volume of 1,659,159. The company has a quick ratio of 0.82, a current ratio of 0.82 and a debt-to-equity ratio of 2.19. The business's fifty day moving average is $151.96 and its 200-day moving average is $172.17. The stock has a market capitalization of $28.15 billion, a price-to-earnings ratio of 22.17, a PEG ratio of 1.84 and a beta of 1.30. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $252.88.
IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.63 by $0.07. The business had revenue of $3.83 billion during the quarter, compared to analyst estimates of $3.77 billion. IQVIA had a return on equity of 29.16% and a net margin of 8.61%. The business's revenue for the quarter was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.54 EPS. As a group, equities analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.
Analysts Set New Price Targets
IQV has been the subject of several recent research reports. Mizuho lowered their price objective on shares of IQVIA from $210.00 to $190.00 and set an "outperform" rating for the company in a research report on Thursday, May 15th. Robert W. Baird decreased their target price on shares of IQVIA from $195.00 to $161.00 and set a "neutral" rating for the company in a research note on Wednesday, May 7th. Citigroup reaffirmed a "neutral" rating on shares of IQVIA in a research note on Thursday, May 22nd. HSBC cut shares of IQVIA from a "buy" rating to a "hold" rating and decreased their price objective for the company from $260.00 to $160.00 in a research report on Friday, April 25th. Finally, Barclays dropped their target price on IQVIA from $170.00 to $165.00 and set an "equal weight" rating on the stock in a research report on Wednesday, May 7th. Eight investment analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $222.45.
Check Out Our Latest Research Report on IQVIA
IQVIA Company Profile
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Further Reading
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
